Tin tức & Cập nhật

A microsimulation study conducted by researchers from the University of Hong Kong (HKU), Guangzhou Medical University, and Shanghai Jiao Tong University shows that prostate-specific antigen (PSA) screening would be highly cost-effective and significantly improve survival outcomes for patients with prostate cancer in China.

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Combining toripalimab with gemcitabine and cisplatin chemotherapy is safe and efficacious in patients with muscle-invasive bladder cancer (MIBC), demonstrating its potential as a neoadjuvant treatment (NAT) in a phase II clinical trial.

Results from the final analysis of the phase III ALIGN trial continue to support the efficacy and safety of atrasentan for the treatment of IgA nephropathy (IgAN).

New drug applications approved by US FDA as of 16-31 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A recent study suggests that awake bladder botulinum toxin injections are feasible in children with neurogenic bladder.

In men with hypogonadism who have undergone radical prostatectomy for low-grade prostate cancer, testosterone replacement therapy (TRT) helps improve sexual and physical function, according to the SPIRIT study.

Nitrofurantoin performs better than single-dose fosfomycin in the treatment of uncomplicated urinary tract infections (UTIs) in women in the primary care setting, according to the SCOUT trial.